Literature DB >> 27123126

Dermatomyositis as a symptom of primary lung cancer: A case report and review of the literature.

Xiangwei Zhang1, Yang Wang2, Guoyuan Ma1, Lin Zhang1, Haiyan Jing3, Jiajun DU1.   

Abstract

Dermatomyositis (DM) is a rare autoimmune disease associated with manifestations of proximal muscle weakness and typical cutaneous skin rash. Patients with DM have a higher incidence rate of cancer, compared with the general population, since DM usually presents as a paraneoplastic syndrome. The present study reports a case of a 69-year-old male patient presenting with typical cutaneous rash and aggravating proximal muscle weakness for 3 months. When first admitted to the Department of Dermatology of Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China), the patient was diagnosed with DM. Subsequently, chest computed tomography scan revealed a neoplasm located in the right upper lobe. Video-assisted thoracoscopic surgery right upper lobectomy and lymph node dissection were then performed. The patient experienced a fast recovery from the surgery. The removal of the neoplasm clearly improved the symptoms of DM. Considering that DM is usually associated with the existence of a tumor, cases of DM require a thorough diagnostic investigation in order to exclude an underlying malignancy.

Entities:  

Keywords:  dermatomyositis; primary lung cancer; surgery

Year:  2016        PMID: 27123126      PMCID: PMC4841099          DOI: 10.3892/ol.2016.4418

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

1.  Relation between dermatomyositis and polymyositis and cancer.

Authors:  J P Callen
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

Review 2.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

3.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

Review 4.  Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature.

Authors:  J Fujita; M Tokuda; S Bandoh; Y Yang; Y Fukunaga; S Hojo; Y Ueda; N Dobashi; K Dohmoto; T Ishida; J Takahara
Journal:  Rheumatol Int       Date:  2001-02       Impact factor: 2.631

Review 5.  Pulmonary complications of polymyositis and dermatomyositis.

Authors:  Maryam Fathi; Ingrid E Lundberg; Göran Tornling
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

Review 6.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

7.  Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study.

Authors:  Csilla András; Andrea Ponyi; Tamás Constantin; Zoltán Csiki; Eva Szekanecz; Peter Szodoray; Katalin Dankó
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

Review 8.  The new lung cancer staging system.

Authors:  Frank C Detterbeck; Daniel J Boffa; Lynn T Tanoue
Journal:  Chest       Date:  2009-07       Impact factor: 9.410

9.  Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.

Authors:  Yuan-Sheng Zang; Qing-Yu Xiu; Zheng Fang; Bing Li; Tian-Bao Xia
Journal:  Oncologist       Date:  2008-01

Review 10.  Malignancy in patients with inflammatory myopathy.

Authors:  Rachelle Buchbinder; Catherine L Hill
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.686

View more
  1 in total

1.  Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.

Authors:  Andrew J Beel; David S Demos; Alfred Chung; Charles Liao; Natalie S Lui
Journal:  J Cardiothorac Surg       Date:  2018-02-07       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.